Response to PEG IFN-α-2b by disease status and prior response to IFN-α
| . | Treated . | PHR . | CHR . | Cytogenetic response . | ||
|---|---|---|---|---|---|---|
| Minor . | Partial . | Complete . | ||||
| Disease status | ||||||
| Active | 19 | 3 | 7 | — | — | 2 |
| CHR | 8 | NA | NA | — | 3 | 4 |
| Status prior to therapy | ||||||
| Hematologic resistance to IFN-α | 9 | — | 4 | — | — | — |
| Cytogenetic status prior to PEG IFN-α-2b | ||||||
| Ph 95%-100% | 11 | — | NA | — | — | 2 |
| Ph 50%-75% | 4 | — | NA | — | 2 | 2 |
| Ph 15%-35% | 3 | — | NA | — | 1 | 2 |
| Intolerance to IFN-α | 6 | — | — | — | 1 | 3 |
| . | Treated . | PHR . | CHR . | Cytogenetic response . | ||
|---|---|---|---|---|---|---|
| Minor . | Partial . | Complete . | ||||
| Disease status | ||||||
| Active | 19 | 3 | 7 | — | — | 2 |
| CHR | 8 | NA | NA | — | 3 | 4 |
| Status prior to therapy | ||||||
| Hematologic resistance to IFN-α | 9 | — | 4 | — | — | — |
| Cytogenetic status prior to PEG IFN-α-2b | ||||||
| Ph 95%-100% | 11 | — | NA | — | — | 2 |
| Ph 50%-75% | 4 | — | NA | — | 2 | 2 |
| Ph 15%-35% | 3 | — | NA | — | 1 | 2 |
| Intolerance to IFN-α | 6 | — | — | — | 1 | 3 |
Entries are numbers of patients. Patient with accelerated phase CML and ≥ 15% blasts returned to second chronic phase, but is evaluated as resistant because he did not achieve PHR or CHR (patient 26 in Table 5).
NA indicates not applicable.